News Releases

SenesTech Announces Progress and Expansion of Washington DC ContraPest® Deployment

FLAGSTAFF, Ariz., Feb. 26, 2019 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today further progress on deployment planning and expansion of scope for fertility control in the city of Washington DC.

SenesTech, Inc. has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company's first fertility control product, ContraPest(R), is marketed for use initially in controlling rat infestations. (PRNewsfoto/SenesTech, Inc.)

"Last Wednesday, in a meeting with Gerard Brown, Washington DC's Program Manager, Rodent and Vector Control Division, we discussed the planned deployment of ContraPest in Washington DC. We have agreed to assist the City in optimizing that deployment, as well as how best to expand deployment beyond the initial wards to all eight wards of the City," said Brandy Pyzyna, Vice President  of Scientific Operations of SenesTech. "Maintaining a close collaboration allows us to bring our unique approach to the City's integrated rodent management plan."

"The strength of our technology lies in the ability to work closely with our customers to design, plan and review large impact projects such as Washington DC for successful rodent population decline and management.  Mr. Brown has been an outstanding partner in the careful assessment of the City's rodent issues and embracing new ideas to pursue the most successful outcome possible.  We are excited to work with him as the City adds fertility control to their all-encompassing approach, and jointly implement a 21st century smart approach to rodent control," said Dr. Loretta Mayer, CEO and co-founder of SenesTech.

A comprehensive roll-out of the ContraPest product will commence in spring. ContraPest has been delivered and is in place for deployment with the first ward. Sequential deployments are now planned throughout all eight wards.  The City of Washington DC and SenesTech have agreed that this will provide the City with the best deployment strategy for coverage and maintenance.  SenesTech is working in several municipal and other locations with similar deployment strategies to that of Washington DC, who will subsequently benefit from the close working relationship with Mr. Brown and his colleagues.   

Dr. Mayer concluded, "Bringing a new approach to a century's old problem requires the commitment and vision of an entire community.  We applaud the City of Washington DC in their dedication to creating a safe, sanitary and forward-looking community."

About SenesTech 

SenesTech is changing the paradigm of pest management by targeting the root cause of the problem: reproduction.

ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.

We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at

Safe Harbor Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. Forward looking statements include, but are not limited to, our expectations regarding: the outcome of our efforts in Washington DC, the timing and scope of the ContraPest roll-out and any sequential deployments, and our belief that our product is more humane, less harmful to the environment and more effective than traditional methods.  All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.


SOURCE SenesTech, Inc.

For further information: Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700,, Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143